[EUROASPIRE III: a comparison between Turkey and Europe].
暂无分享,去创建一个
O. Ergene | L. Tokgözoğlu | E. Kaya | Ç. Erol | E. B. Kaya
[1] J. Schölmerich,et al. Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension. , 2009, American Journal of Physiology - Gastrointestinal and Liver Physiology.
[2] K. Kotseva,et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.
[3] Lale Tokgözo gcaron,et al. Atherosclerotic vascular disease and risk factors in Turkey: from past to present. , 2008 .
[4] Shah Ebrahim,et al. Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) , 2007 .
[5] Shah Ebrahim,et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.
[6] Alan D. Lopez,et al. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.
[7] A. Oguz,et al. Treatment and control of hypertension in Turkish population: a survey on high blood pressure in primary care (the TURKSAHA study) , 2006, Journal of Human Hypertension.
[8] U. Hodoğlugil,et al. Smoking and obesity make a bad problem worse: genetics and lifestyle affect high density lipoprotein levels in Turks. , 2006, Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology.
[9] G. Nergizoğlu,et al. Prevalence, awareness, treatment and control of hypertension in Turkey (the PatenT study) in 2003 , 2005, Journal of hypertension.
[10] Steven Hawken,et al. Preventive cardiologyAbstractsEffect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study , 2004 .
[11] S. Ebrahim,et al. Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials. , 2004, The American journal of medicine.
[12] H. King,et al. Population-based study of diabetes and risk characteristics in Turkey: results of the turkish diabetes epidemiology study (TURDEP). , 2002, Diabetes care.
[13] C. Schindler,et al. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. , 2002, The American journal of medicine.
[14] A. Onat. Risk factors and cardiovascular disease in Turkey. , 2001, Atherosclerosis.
[15] D. Cook,et al. Effect of smoking cessation on mortality after myocardial infarction: meta-analysis of cohort studies. , 2000, Archives of internal medicine.
[16] R. Mahley,et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. , 1995, Journal of lipid research.
[17] David R. Wood,et al. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. , 2001, European heart journal.
[18] A. Onat,et al. Prevalence of All-cause and Coronary Mortality in Turkish Adults as Assessed by 8-year Follow-up Data of the Turkish Adult Risk Factor Study , 1999 .
[19] K. Anderson,et al. An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.